Where does Nurix Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$87.17M-11.4%	-$78.22M+9.5%	-$86.42M-98.8%	-$43.46M+22.9%	-$56.35M+3.8%
Depreciation and amortization	$2.2M+3.6%	$2.12M+4.5%	$2.03M-9.5%	$2.24M-4.6%	$2.35M-7.8%
Stock-based compensation	$9.4M+3.5%	$9.09M-7.0%	$9.77M-5.9%	$10.39M+19.1%	$8.72M+2.5%
Gain (loss) on sale of assets	-$160K—	——	——	——	$0+100%
Change in accounts payable	-$461K—	——	——	-$2.68M+16.5%	-$3.21M-142%
Change in accrued liabilities	$4.12M-62.7%	$11.04M+74.3%	$6.34M+190%	-$7.01M-201%	$6.94M-23.1%
Change in other assets	-$1.29M-200%	$1.28M-35.2%	$1.98M—	——	$6.25M+410%
Change in deferred revenue	-$1.25M+90.8%	-$13.58M-72.0%	-$7.89M-38.9%	-$5.68M+42.2%	-$9.83M+26.0%
Non-cash operating lease expense	$1.58M-37.1%	$2.51M-15.5%	$2.97M+4.1%	$2.86M+60.6%	$1.78M+1.4%
Change in operating lease liabilities	$205K+127%	-$756K+38.6%	-$1.23M+12.1%	-$1.4M+16.7%	-$1.68M-1.8%
Net cash from operating activities	-$71.91M-6.0%	-$67.83M-18.2%	-$57.39M+9.1%	-$63.16M-3.4%	-$61.09M-25.3%
Capital expenditures	$1.05M-79.6%	$5.13M+89.3%	$2.71M+1.3%	$2.68M-23.2%	$3.49M+65.6%
Proceeds from maturities/sales of investments	$133.15M-26.0%	$179.82M+15.1%	$156.19M+9.7%	$142.34M+2.3%	$139.2M-12.7%
Net cash from investing activities	-$123.83M-35,888%	$346K-99.3%	$50.48M-29.4%	$71.5M+180%	$25.53M+118%
Proceeds from issuance of common stock	$18M—	$0—	$0—	$0—	$0-100%
Net cash from financing activities	$19.98M-91.5%	$236.01M+20,334%	$1.16M+19,150%	$6K-99.6%	$1.47M-99.3%
Net increase (decrease) in cash	-$175.77M-204%	$168.52M+3,028%	-$5.76M-169%	$8.34M+124%	-$34.08M-411%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.98M+5.9%	$1.87M-15.0%	$2.2M-18.7%	$2.7M-24.1%	$3.56M+1.8%
Gain/(loss) on dispositions, net	-$160K—	——	——	——	$0+100%
Operating lease liabilities	$205K+127%	-$756K+38.6%	-$1.23M+12.1%	-$1.4M+16.7%	-$1.68M-1.8%
Other current liabilities	$4.12M-62.7%	$11.04M+74.3%	$6.34M+190%	-$7.01M-201%	$6.94M-23.1%
Increase (Decrease) in Prepaid Expense and Other Assets	-$1.29M-200%	$1.28M-35.2%	$1.98M—	——	$6.25M+410%
Operating lease right-of-use asset amortization	$1.58M-37.1%	$2.51M-15.5%	$2.97M+4.1%	$2.86M+60.6%	$1.78M+1.4%
Proceeds from disposition of marketable securities and other investments	$133.15M-26.0%	$179.82M—	——	——	$139.2M-12.7%
Issuance of stock under employee stock plans	$1.6M—	——	$977K—	——	$1.25M—
Accrued payables for capital expenditures	$1.7M—	——	$1.04M—	——	$1.2M+3.1%
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities	——	$0—	$0—	$0—	$0-100%
Increase Decrease In Contract With Customer Liability	-$1.25M+90.8%	-$13.58M-72.0%	-$7.89M-38.9%	-$5.68M+42.2%	-$9.83M+26.0%
Increase Decrease In Operating Lease Liability	$205K+127%	-$756K+38.6%	-$1.23M+12.1%	-$1.4M+16.7%	-$1.68M-1.8%
Issuance costs related to equity financing included in accrued expenses and other current liabilities	——	$92.75K0.0%	$92.75K0.0%	$92.75K0.0%	$92.75K—
Leased assets obtained in exchange for operating lease liabilities	$2.72M—	$0-100%	$5.79M-78.3%	$26.71M—	$0-100%
Free cash flow	-$72.96M0.0%	-$72.96M-21.4%	-$60.1M+8.7%	-$65.84M-2.0%	-$64.57M-27.0%
Free cash flow	-$72.96M0.0%	-$72.96M-21.4%	-$60.1M+8.7%	-$65.84M-2.0%	-$64.57M-27.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Nurix Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.